{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-078323","form_type":"8-K","ticker":"PAHC","cik":"0001069899","company_name":"PHIBRO ANIMAL HEALTH CORP","filed_at":"2026-06-26T21:07:54+00:00","discovered_at":"2026-06-26T21:10:00.286903+00:00","generated_at":"2026-06-26T21:10:18.582482+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Phibro Animal Health appoints Daniel Bendheim as CEO effective July 1, 2026, with performance-based RSU grant","bullets":["Daniel Bendheim appointed CEO & President effective July 1, 2026; base salary $850k, target bonus 50% of salary.","Granted 300,000 performance-based RSUs vesting based on 90-day average stock price from $70 to $100+ by June 30, 2031.","Severance: 18 months COBRA if terminated without cause; 6 months base salary for death/disability.","Employment agreement includes confidentiality, non-compete, non-solicitation, non-disparagement covenants."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-078323","json":"https://secwatch.observer/filing/0001104659-26-078323.json","markdown":"https://secwatch.observer/filing/0001104659-26-078323.md","text":"https://secwatch.observer/filing/0001104659-26-078323.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/0001104659-26-078323-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/tm2619111d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-26T21:10:18.582482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"3202850749","claim":"Daniel Bendheim was appointed as Chief Executive Officer and President at PHIBRO ANIMAL HEALTH CORP.","evidence_excerpt":"On June 25, 2026, in connection with Daniel (Dani) Bendheim’s appointment to the role of Chief Executive Officer and President of the Company effective July 1, 2026","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1069899/000110465926078323/0001104659-26-078323-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Chief Executive Officer and President"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}